A real-world study on the efficacy and safety of inetetamab in the treatment of advanced breast cancer
Objective To observe the efficacy and safety of inetetamab in the treatment of advanced breast cancer in the real-world.Methods A retrospective analysis was performed on 63 patients with advanced breast cancer admitted to Xiangyang Central Hospital from August 2020 to August 2022.Survival curve was plotted by Kaplan-Meier method and performed with Log-rank test.Cox proportional risk model was used to analyze the risk factors affecting the prognosis,and non-parametric test Kruskal-Wallis was used to analyze the difference in treatment efficacy among different subgroups.Results The objective response rate(ORR)of 63 patients was 47.6%(30/63),and the disease control rate(DCR)was 66.7%(42/63).The ORR and DCR of the patients treated with first-line and second-line inetetamab were 85.0%and 90.0%,and those treated with third-line to seventh-line inetetamab were 30.2%and 55.8%,respectively,and the difference between the two groups was statistically significant(P<0.05).The ORR and DCR of patients who had previously used trastuzumab and tyrosine kinase inhibitor(TKI)were 31.0%and 54.8%,respectively,and those who had not used trastuzumab and TKI before were 81.0%and 90.5%,respectively,and the difference between the two groups was statistically significant(P<0.05).The median progression-free survival(PFS)for all patients was 5 months.Univariate analysis showed that the number of treatment lines,number of metastatic sites,previous use of trastuzumab and TKI drugs,and efficacy were all related to prognosis(P<0.05).Multivariate analysis showed that efficacy evaluation was an independent prognostic factor(P<0.05).The incidence of grade 3-4 adverse reactions was 9.5%(6/63),including 1 case of thrombocytopenia,1 case of anemia,2 cases of renal insufficiency,and 2 cases of diarrhea.Conclusion The efficacy of inetetamab in the treatment of advanced breast cancer is definite,and the adverse reactions are controllable,which has good clinical application value.
NETL
NSTL
万方数据
